^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes

Excerpt:
Of 139 pts treated with Len as monotherapy or in combination for at least 2 cycles included, 118 (85%) had MDS...Association rules identified the following combinations of genomic/cytogenetic abnormalities to predict response to Len in non-del(5q): (DDX41, NK) and (MECOM, KDM6A/KDM6B).
DOI:
10.1182/blood-2018-99-114681